Read by QxMD icon Read

Pneumococcal vaccine in adults

Céline Maréchal, Himal Lal, Airi Poder, Murdo Ferguson, Igwebuike Enweonye, Thomas C Heineman, Caroline Hervé, Paul Rheault, Jaak Talli, Dominique Wauters, Lidia Oostvogels
BACKGROUND: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) when the first dose was co-administered with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged ≥50 years. METHODS: In this open label, multi-center study (NCT02045836), participants were randomized 1:1 to receive either the first dose of RZV and PPSV23, co-administered at Day 0 and the second dose of RZV at Month 2 (Co-Ad group), or PPSV23 at Day 0, the first dose of RZV at Month 2 and second dose of RZV at Month 4 (Control group)...
June 11, 2018: Vaccine
Ranjith Jayaraman, Rosemol Varghese, Jones Lionel Kumar, Ayyanraj Neeravi, Devika Shanmugasundaram, Ravikar Ralph, Kurien Thomas, Balaji Veeraraghavan
PURPOSE: To investigate the epidemiology of invasive pneumococcal disease (IPD), prevalent serotypes, and pattern of antimicrobial resistance (AMR) in Indian adults. METHODS: Prospective laboratory based surveillance of IPD was carried out in >18 years age group between January 2007 and July 2017, from a tertiary care hospital in South India. All Streptococcus pneumoniae culture positives from blood, CSF and sterile body fluids were characterized to identify the serotypes and AMR...
May 22, 2018: Journal of Microbiology, Immunology, and Infection, Wei Mian Yu Gan Ran za Zhi
M Tashani, M Alfelali, O Barasheed, A S Alqahtani, L Heron, M Wong, H Rashid, H Findlow, R Borrow, R Booy
Hajj pilgrims are susceptible to several serious infections and are required to receive multiple vaccinations. Polysaccharide-protein conjugate vaccines contain carrier proteins such as tetanus toxoid (TT), diphtheria toxoid or a mutant of diphtheria toxoid (CRM197). These carrier proteins may interact with other conjugate or combination vaccines containing tetanus or diphtheria on concurrent or sequential administration. We examined the immune interaction of separate and concomitant administration of a tetanus/diphtheria/acellular pertussis (Tdap) vaccine with a TT-conjugated quadrivalent meningococcal vaccine (MCV4) (coadministered with 13-valent pneumococcal CRM197-conjugate vaccine [PCV13]) in adult Australian pilgrims before attending Hajj in 2015...
June 4, 2018: Vaccine
Angela R Branche, Hongmei Yang, James Java, Jeanne Wiltse-Holden, David J Topham, Michael Peasley, Michael R Frost, Moon H Nahm, Ann R Falsey
INTRODUCTION: Pneumococcus is a commensal of the upper respiratory tract and colonization is common in young children. Carriage studies have provided insights on vaccine effects in children and may also be useful for assessing vaccines in adults. However, culture based prevalence studies in older adults describe low colonization rates. Therefore, we assessed cumulative incidence of pneumococcal colonization in older adults using polymerase chain reaction (PCR) targeting the lytA gene and risk factors for carriage...
June 2, 2018: Vaccine
Bradford D Gessner, Qin Jiang, Cornelis H Van Werkhoven, Heather L Sings, Chris Webber, Daniel Scott, Kathleen M Neuzil, Katherine L O'Brien, Richard G Wunderink, Diederick E Grobbee, Marc J M Bonten, Luis Jodar
BACKGROUND: We conducted a post-hoc analysis of a double blind, randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged 65 years or older to assess public health impact. METHODS: For all outcomes, we included all randomized subjects, using a modified intention-to-treat (mITT) approach to determine vaccine efficacy (VE), vaccine preventable disease incidence (VPDI) defined as control minus vaccinated group incidence, and numbers needed to vaccinate (NNV) (based on a five-year duration of protection)...
May 31, 2018: Vaccine
R Willis, M Smikle, O Heslop, N Bodonaik, M Thame, U Kumar, M Aung, A Kellier, S Drysdale, V Leon
BACKGROUND: Pneumococcal serotypes circulating in any population vary over time and between countries and impacts the effectiveness of pneumococcal vaccination. OBJECTIVE: This study investigated the epidemiology of pneumococcal disease in Jamaica. METHODS: Streptococcus pneumoniae isolates (n= 349) along with demographic and clinical information were collected from patients presenting at the 4 major hospitals in Jamaica over a 2-year period...
May 16, 2018: Human Antibodies
Mike Recher, Julia R Hirsiger, Marc B Bigler, Martin Iff, Barbara Lemaître, Kathrin Scherer, Peter Häusermann, Claire-Anne Siegrist, Christoph T Berger
Pneumococcal conjugate vaccine (PCV) is recommended for adults with chronic disease. Extensive limb swelling (ELS) is an acute vigorous local inflammatory reaction following vaccination. Predisposing immune system correlates and the influence of ELS on vaccine responses are not known. Here, we report a case of a 67-year-old woman with a history of multiple pneumonias who had a detailed immunological work-up pre-vaccination because of suspected immunodeficiency. Four days following a first vaccination with PCV13 she developed ELS-mimicking erysipelas...
2018: NPJ Vaccines
Ulrike Kuchenbecker, Daniela Chase, Anika Reichert, Julia Schiffner-Rohe, Mark Atwood
INTRODUCTION: In Germany, a 23-valent polysaccharide pneumococcal vaccine (PPSV23) is recommended for elderly (60+) and patients 16+ with chronic diseases not associated with immune suppression. For all other patients at risk, sequential immunization with a 13-valent pneumococcal conjugate vaccine (PCV13) first, followed by PPSV23 is recommended. Repeated vaccination with PPSV23 is recommended every 6 years after individual assessment by the physician. This was adopted into the vaccination directive with binding reimbursement and funding...
2018: PloS One
Jonathan Jolin, Robertus van Aalst, Bryan Volpp, Thomas Taylor, Emily Cohen
BACKGROUND: Pneumococcal infections are an important source of morbidity and mortality in older adults and persons with compromised immune systems. New recommendations from the Advisory Committee on Immunization Practices (ACIP) became available September 2014, which included recommendations for the use of the 13-valent pneumococcal conjugate vaccine (PCV13). A study was conducted to increase the PCV13 vaccination rates of hospitalized patients at the White River Junction Veterans Affairs Medical Center (White River Junction, Vermont) through the use of a resident-driven quality improvement (QI) project...
June 2018: Joint Commission Journal on Quality and Patient Safety
John M McLaughlin, Qin Jiang, Raul E Isturiz, Heather L Sings, David L Swerdlow, Bradford D Gessner, Ruth M Carrico, Paula Peyrani, Timothy L Wiemken, William A Mattingly, Julio A Ramirez, Luis Jodar
Background: Following universal recommendation for use of 13-valent pneumococcal conjugate vaccine (PCV13) in US adults aged ≥65 years in September 2014, we conducted the first real-world evaluation of PCV13 vaccine effectiveness (VE) against hospitalized vaccine-type community-acquired pneumonia (CAP) in this population. Methods: Using a test-negative design, we identified cases and controls from a population-based surveillance study of adults in Louisville, Kentucky, who were hospitalized with CAP...
May 21, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Rebecca Culver Clark, Kimberly Ferren Carter, Julie Jackson, Deborah Hodges
The purpose of this quality improvement study was to explore the impact of audit and feedback on the pneumococcal immunization rate for at-risk adults in ambulatory settings. Study findings support the hypothesis that timely, individualized audit and feedback can have a positive impact on immunization rate; generalized feedback that did not provide actionable information did not have the same impact. The difference between the interventions was significant, χ (1, N = 1993) = 124.7, P <.001.
July 2018: Journal of Nursing Care Quality
Wen-Yen Chiou, Moon-Sing Lee, Shih-Kai Hung, Hon-Yi Lin, Yuan-Chen Lo, Feng-Chun Hsu, Shiang-Jiun Tsai, Chung-Yi Li
OBJECTIVE: The Advisory Committee on Immunization Practices in 2012 recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults with high risk of pneumonia. However, its effectiveness in cancer survivors has not been investigated. Our aim was to investigate the effectiveness of PPSV23 in these patients. DESIGN: Population-based matched cohort study. SETTING: Claim data were obtained from 1 million people registered with the National Health Insurance Research Database in 1996, and followed to 2010...
May 16, 2018: BMJ Open
Soumi Ray, Dustin S McEvoy, Skye Aaron, Thu-Trang Hickman, Adam Wright
Objective: Malfunctions in Clinical Decision Support (CDS) systems occur due to a multitude of reasons, and often go unnoticed, leading to potentially poor outcomes. Our goal was to identify malfunctions within CDS systems. Methods: We evaluated 6 anomaly detection models: (1) Poisson Changepoint Model, (2) Autoregressive Integrated Moving Average (ARIMA) Model, (3) Hierarchical Divisive Changepoint (HDC) Model, (4) Bayesian Changepoint Model, (5) Seasonal Hybrid Extreme Studentized Deviate (SHESD) Model, and (6) E-Divisive with Median (EDM) Model and characterized their ability to find known anomalies...
May 11, 2018: Journal of the American Medical Informatics Association: JAMIA
Masafumi Seki, Bin Chang, Kengo Ohshima, Yuji Watanabe
We present two adult cases of pneumococcal severe arthritis one case with, and other case without pericarditis those occurred in one season. Both cases eventually recovered, and the isolated S. pneumoniae strains were serotype 12F and penicillin susceptible. The patients were not elderly and had no medical history including pneumonia and vaccination. Although S. pneumoniae is a relatively rare causative pathogen of arthritis and/or pericarditis recently, a greater number of cases may be expected as a result of serotype conversion due to the increased use of pneumococcal conjugate vaccines in Japan...
2018: IDCases
James L Lin, Jennifer L Bacci, Marci J Reynolds, Yushi Li, Rachel G Firebaugh, Peggy S Odegard
OBJECTIVE: To compare the impact of a whole-staff training strategy to a train-the-trainer strategy on 1) the number of influenza, pneumococcal, herpes zoster, and pertussis vaccines administered by community pharmacists to adults; 2) staff confidence; and 3) fidelity to the intervention. SETTING: Eight Quality Food Centers (QFC) Pharmacies in Seattle, Washington. PRACTICE DESCRIPTION: QFC Pharmacy is a grocery store division of The Kroger Co...
May 9, 2018: Journal of the American Pharmacists Association: JAPhA
Luz Elena Espinosa de Los Monteros-Pérez, Rodolfo Norberto Jiménez-Juárez, Demóstenes Gómez-Barreto, Carlos Francisco Navas-Villar
INTRODUCTION: Streptococcus pneumoniae (Sp) is the main cause of community-acquired pneumonia in the elderly, hence the importance to establish the prevalence of nasopharyngeal colonization by different Sp serotypes in adults. METHODS: from December 2009 to June 2010, nasopharyngeal cultures were taken from adults living in rural communities in Mexico for the isolation and serotyping of Sp by the Quellung reaction. Penicillin and ceftriaxone susceptibility tests were performed by the microdilution method...
May 7, 2018: Enfermedades Infecciosas y Microbiología Clínica
Sean T O'Leary, David W Kimberlin, Yvonne A Maldonado
The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, each of whom is appointed to a 4-year term. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. The ACIP met on October 25 and 26, 2017, to discuss herpes zoster vaccine, the child/adolescent and adult vaccination schedules, Japanese encephalitis (JE) epidemiology and vaccines, pneumococcal vaccines, anthrax vaccines and disaster preparedness, hepatitis A outbreaks, influenza surveillance and vaccination coverage, vaccine safety, and considerations for a potential third dose of measles-mumps-rubella (MMR) vaccine to combat ongoing mumps outbreaks...
May 15, 2018: Journal of the Pediatric Infectious Diseases Society
Laura Kaplan-Weisman, Eve Waltermaurer, Casey Crump
The herpes zoster (shingles) vaccine is recommended for all adults aged ≥ 60 years without contraindications to prevent shingles and post-herpetic neuralgia. There are no published studies on zoster vaccination rates, barriers, or workflows in adults who have experienced homelessness. Due to barriers specific to this vaccine, including difficulty determining insurance coverage, high upfront costs, need for storage in a freezer, and under-prescription by physicians, uptake is lower compared to other recommended vaccines for older adults...
May 5, 2018: Journal of Community Health
John D Mooney, Michael Imarhiagbe, Jonathan Ling
A recently reported steep increase in the incidence of invasive pneumococcal disease (IPD) in adults in the North East of England was primarily associated with pneumococcal sero-types found in the 23-valent pneumococcal polysaccharide vaccine (PPSV23). This region also has one of the highest rates of alcohol-related premature mortality and morbidity in the UK. Given that alcohol dependence is long acknowledged as one of the strongest risk factors for IPD mortality, we feel there is an increasingly compelling case to look again at the divergence of UK vaccine guidance from that of the World Health Organisation and the Centre for Disease Control in the USA, in the non-inclusion of alcoholism as an indicator condition that would potentially benefit from receiving PPSV23 vaccine...
May 2, 2018: Vaccines
Yiling Jiang, Xiaoqin Yang, Kazuko Taniguchi, Tanaz Petigara, Machiko Abe
OBJECTIVE: In Japan, the National Immunization Program (NIP) includes PPV23 as the primary vaccination for adults and catch-up cohorts. The Japanese Association for Infectious Diseases recommends revaccination for older adults who received primary vaccination ≥5 years earlier. The cost-effectiveness of adding revaccination and/or continuing catch-up vaccination in the NIP was evaluated from the public payer perspective in Japan. METHODS: The Markov model included five health states: no pneumococcal disease, invasive pneumococcal diseases (IPD), non-bacteremic pneumococcal pneumonia (NBPP), post-meningitis sequelae, and death...
May 3, 2018: Journal of Medical Economics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"